Cognito Therapeutics Partners with Initiative to Change the "D-Word," Commits to Eliminating Use of "Dementia" Across All Communications

Cognito Therapeutics Partners with Initiative to Change the "D-Word," Commits to Eliminating Use of "Dementia" Across All Communications ...
Business Wire

Cognito Therapeutics Announce OVERTURE I Study Demonstrated Significant Time Savings Using Composite Measures of Function and Cognition

Spectris AD™ meaningfully reduced functional and cognitive decline in Alzheimer’s Disease over 6 months compared to sham treatment and was associated with 60-84% time savings. OVERTURE I Phase 2 MRI ...

Cognito Therapeutics raises $105m for Alzheimer’s therapeutic advancement

With a pivotal trial readout for Cognito’s Spectris due later this year, the company anticipates launching the Alzheimer’s disease therapeutic in the US by 2027.
Business Wire

Cognito Therapeutics Announces Spectris™ Treatment Demonstrates Myelin and Synaptic Biomarker Changes in Alzheimer’s Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in ...